Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) insider Penka Petrova sold 2,708 shares of the firm’s stock in a transaction that occurred on Thursday, January 7th. The stock was sold at an average price of $14.71, for a total value of $39,834.68. Following the transaction, the insider now owns 2,708 shares in the company, valued at $39,834.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
TRIL opened at $14.51 on Thursday. The stock has a market cap of $1.46 billion, a PE ratio of -5.90 and a beta of 2.04. The business has a 50 day moving average of $14.58 and a 200-day moving average of $12.30. Trillium Therapeutics Inc. has a 52 week low of $2.26 and a 52 week high of $20.96.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Sunday, November 15th. The biotechnology company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.33). Sell-side analysts predict that Trillium Therapeutics Inc. will post -1.53 EPS for the current fiscal year.
Several research firms have weighed in on TRIL. ValuEngine cut Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 1st. Craig Hallum increased their price objective on Trillium Therapeutics from $15.00 to $21.00 in a report on Wednesday, November 18th. Bloom Burton cut Trillium Therapeutics from a “buy” rating to an “accumulate” rating in a report on Tuesday, December 8th. HC Wainwright increased their price objective on Trillium Therapeutics from $16.50 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, November 18th. Finally, Evercore ISI began coverage on Trillium Therapeutics in a report on Monday, October 12th. They issued an “outperform” rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $17.85.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Dual Listing What You Need to Know
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.